Skip to main content
. 2019 Aug 15;16(1):33–41. doi: 10.1080/21645515.2019.1643675

Figure 5.

Figure 5.

Safety and tolerability of RTS,S/AS01 with and without antimalarial drug administrations a Percentage of mild, moderate, severe adverse (AEs) in each treatment group b The number of AEs per person and the frequency of participants with a specific number of AE c Summary of AEs by frequency.